Navigation Links
Natural Alternatives International, Inc. Announces Fiscal 2013 Q3 and YTD Results

SAN MARCOS, Calif., May 14, 2013 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $178,000 or $0.03 per diluted share on net sales of $15.8 million for the quarter ended March 31, 2013. 

Net sales for the three months ended March 31, 2013 decreased $1.6 million or 9.1% from $17.4 million recorded in the comparable prior year period.  For the quarter ended March 31, 2013, contract manufacturing sales decreased $438,000 or 2.9% from the comparable quarter last year due primarily to lower sales to existing customers, lower average sales prices for a portion of our higher volume products and lower average EUR exchange rates. Patent and trademark licensing revenue decreased 51.8% to $1.0 million during the quarter ended March 31, 2013 as compared to $2.1 million for the prior year period. This decrease resulted from lower patent licensing fee payments totaling $654,000 along with a reduction in beta-alanine raw material sales totaling $418,000. This licensing revenue was generated from our patent estate pursuant to license and supply agreements with third parties for the use and distribution of the ingredient known as beta-alanine sold under our CarnoSyn® trade name.  Our branded products sales totaled $321,000 for the third quarter of fiscal 2013 as compared to $387,000 for the comparable prior year period.

Net sales for the nine months ended March 31, 2013 decreased to $46.0 million or 11.5% from $51.9 million recorded in the comparable prior year period.  Contract manufacturing sales during the first nine months of fiscal 2013 decreased $4.8 million or 10.3% from the comparable prior year period and patent and trademark licensing revenue decreased 22.7% or $939,000 during this same period. Our branded products sales decreased $191,000 or 16.0% for the first nine months of fiscal 2013.

Net income for the first nine months of fiscal 2013 totaled $977,000 or $0.14 per diluted share compared to net income of $3.4 million or $0.48 per diluted share in the comparable prior year period. The decrease was primarily attributable to lower contract manufacturing sales and patent and trademark licensing revenue, increased raw material and manufacturing production costs, unfavorable foreign currency exchange rates and increased patent and prosecution expenses which totaled $1.8 million for the first nine months of fiscal 2013.

As of March 31, 2013, we had cash of $14.6 million and working capital of $28.6 million compared to $14.5 million and $27.7 million, respectively, as of June 30, 2012.  As of March 31, 2013, we had $5.5 million available under our line of credit agreements.

"As anticipated, the quarter ended March 31, 2013 experienced various headwinds, but I am gratified we achieved a profit for the quarter in spite of these factors," noted Chairman and Chief Executive Officer Mark A. Le Doux. "As the Food and Drug Administration continues in its efforts to point out significant failings in compliance of the Good Manufacturing Practices with others in our industry, we continue to receive inquiries from a variety of potential customers who wish to protect their brand reputations by upgrading their supply chain relationships through a partnership with NAI.

"During the current quarter we have begun to see traction building with certain client initiatives which we believe should result in increased orders in future periods.  While we continue to support research in the uses for CarnoSyn® beta-alanine and at the same time actively pursue infringers, we are seeing continued growth in the adoption of CarnoSyn® beta-alanine in more and more product offerings."

NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, market acceptance and media attention towards our CarnoSyn® beta-alanine, our ability to expand our domestic and international contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or

Web site:

 CONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share data)(Unaudited)Three Months EndedNine Months EndedMarch 31,March 31,2013201220132012NET SALES$15,835100.0%$17,422100.0%$45,981100.0%$51,924100.0%Cost of goods sold

13,05782.5%13,29976.3%37,70082.0%39,76576.6%Gross profit

2,77817.5%4,12323.7%8,28118.0%12,15923.4%Selling, general & administrative expenses

2,20914.0%2,49314.3%6,95615.1%6,95613.4%INCOME FROM OPERATIONS5693.6%1,6309.4%1,3252.9%5,20310.0%Other (expense) income, net

(48)-0.3%(19)-0.1%(53)-0.1%370.1%INCOME BEFORE TAXES5213.3%1,6119.2%1,2722.8%5,24010.1%Income tax expense

3435432951,859NET INCOME$
78$   1,068$




6,8446,9796,8916,993 NATURAL ALTERNATIVES INTERNATIONAL, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)March 31June 30,20132012ASSETSCash and cash equivalents

$14,638$14,478Accounts receivable, net

6,1158,751Inventories, net

10,0808,355Deferred income taxes

699699Other current assets

1,8902,236Total current assets

33,42234,519Property and equipment, net

9,71710,647Deferred income taxes

1,4711,471Other noncurrent assets, net

493560Total Assets

$45,103$47,197LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable and accrued liabilities 

$4,794$6,836Deferred rent

300493Total Liabilities

5,0947,329Stockholders' Equity

40,00939,868Total Liabilities and Stockholders' Equity


SOURCE Natural Alternatives International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clove Oil, a Natural Pesticide Used on Apples and Other Fruit, May Cause Dermatitis
2. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
3. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
4. New Research Reveals Some Natural Supplements Effective Against Prostate Cancer
5. LycoRed Group Acquires Vitan, Strengthening its Leadership Position in the Global Natural Carotenoids Market
6. Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer
7. Zarbees Partners with K.I.D.S. by Donating Nearly 23,000 Bottles of All-Natural Cough Syrup to Underserved Families Across the Globe
8. Zarbees Introduces a New Extra Strength Line of Natural Cough Products for Adults and Children 12+ in Time for Cough and Cold Season
9. Tell Your Children They can get Naturally High
10. iSALUS Healthcares chairman receives national honors from Samaritans Purse - an international organization providing spiritual and physical aid to victims of war, poverty, natural disaster and disease.
11. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
(Date:11/25/2015)... ... 25, 2015 , ... The holiday season is jam-packed with ... palates of attendees is of the utmost importance. Whether you are cooking at ... these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... 25, 2015 , ... According to an article published November 10th ... widely heralded as a breakthrough for performing hernia repairs. The article explains that the ... is that it can greatly reduce the pain that a patient might otherwise experience ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
Breaking Medicine News(10 mins):